Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$188 Mln
P/E Ratio
--
P/B Ratio
2.29
Industry P/E
--
Debt to Equity
0.02
ROE
-0.6 %
ROCE
-58.11 %
Div. Yield
0 %
Book Value
1.73
EPS
-0.95
CFO
$-219.70 Mln
EBITDA
$-265.42 Mln
Net Profit
$-264.49 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cardiff Oncology (CRDF)
| -31.22 | -20.40 | -15.68 | -31.54 | 25.78 | 26.27 | -41.33 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cardiff Oncology (CRDF)
| 190.68 | 5.71 | -76.71 | -66.59 | 1,350.81 | -60.67 | -85.61 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company's lead drug candidate is Onvansertib, an oral, small molecule drug candidate that is highly specific for PLK1... inhibition. It also focuses clinical program in indications, such as RAS-mutated metastatic colorectal cancer, as well as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Address: 11055 Flintkote Avenue, San Diego, CA, United States, 92121 Read more
CEO & Director
Dr. Mark Erlander Ph.D.
CEO & Director
Dr. Mark Erlander Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cardiff Oncology Inc (CRDF) stood at $ 97 Mln as on 31-Dec-24
The share price of Cardiff Oncology Inc (CRDF) is $2.99 (NASDAQ) as of 23-Apr-2025 14:42 EDT. Cardiff Oncology Inc (CRDF) has given a return of 25.78% in the last 3 years.
Cardiff Oncology Inc (CRDF) has a market capitalisation of $ 188 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cardiff Oncology Inc (CRDF) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cardiff Oncology Inc (CRDF) and enter the required number of quantities and click on buy to purchase the shares of Cardiff Oncology Inc (CRDF).
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company's lead drug candidate is Onvansertib, an oral, small molecule drug candidate that is highly specific for PLK1 inhibition. It also focuses clinical program in indications, such as RAS-mutated metastatic colorectal cancer, as well as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Address: 11055 Flintkote Avenue, San Diego, CA, United States, 92121
The CEO & director of Dr. Mark Erlander Ph.D.. is Cardiff Oncology Inc (CRDF), and CFO & Sr. VP is Dr. Mark Erlander Ph.D..
There is no promoter pledging in Cardiff Oncology Inc (CRDF).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Cardiff Oncology Inc. (CRDF) | Ratios |
|---|---|
|
Return on equity(%)
|
-59.51
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-6651.68
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cardiff Oncology Inc (CRDF) was $0 Mln.
$-0.07
(
